Top Stories
FDA Approves Veppanu, First-Ever PROTAC, for ESR1-Mutated Breast Cancer
The FDA approved Veppanu (vepdegestrant) on May 1, 2026 — ahead of its June 5 PDUFA date — for adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer after progression on at least one line of endocrine therapy, according to Fierce Pharma. This is the first-ever FDA-approved PROTAC (proteolysis targeting chimera) therapy for any indication. Approval was based on the Phase 3 VERITAC-2 trial: among 270 ESR1-mutated patients, vepdegestrant showed median PFS of 5.0 vs 2.1 months versus fulvestrant (HR 0.57, p=0.0001), with ORR of 19% vs 4%. The FDA also approved the Guardant360 CDx companion diagnostic. Arvinas and Pfizer jointly developed vepdegestrant and are on track to announce a third-party commercialization partner. Arvinas and Pfizer secure landmark first PROTAC approval Fulvestrant faces displacement in ESR1-mutated setting
ODAC Votes 6-3 Against AstraZeneca's Camizestrant ctDNA-Guided Switch Strategy
The FDA's Oncologic Drugs Advisory Committee voted 6-3 on April 30, 2026, that AstraZeneca has not demonstrated clinically meaningful benefit for camizestrant in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after ESR1 mutation detection, per Fierce Biotech. The Phase 3 SERENA-6 trial (315 patients) used a novel ctDNA-guided approach: upon detecting an ESR1 mutation during first-line therapy — but before radiographic progression — patients switched to camizestrant 75 mg daily while continuing their CDK4/6 inhibitor. SERENA-6 showed median PFS of 16.0 vs 9.2 months (HR 0.44) favoring the switch, but the panel questioned whether PFS alone confirmed clinical benefit without mature OS data. The vote threatens AstraZeneca CEO Pascal Soriot's >$5 billion peak sales target for camizestrant. The FDA is not bound by the panel's recommendation. AstraZeneca's first-line switch strategy faces regulatory uncertainty Established CDK4/6 + AI combinations maintain first-line standard
Roche's Giredestrant Meets Primary Endpoint in Phase III lidERA Adjuvant Breast Cancer Trial
Roche's oral SERD giredestrant met its primary endpoint in the Phase III lidERA trial, reducing the risk of invasive disease recurrence or death by 30% (iDFS HR 0.70, 95% CI 0.57–0.87, p=0.0014) versus standard endocrine therapy (tamoxifen or aromatase inhibitors) in 4,170 patients with Stage I–III ER+/HER2- early breast cancer, according to CancerNetwork. Three-year iDFS was 92.4% vs 89.6%. The secondary endpoint of distant recurrence-free interval was also met (HR 0.69), and OS showed a favorable trend (HR 0.79, immature). Giredestrant had a lower discontinuation rate (5.3% vs 8.2%). Results were first reported at SABCS in December 2025. Giredestrant is the first oral SERD to demonstrate superior iDFS in the adjuvant setting. Roche also has an NDA under FDA review for giredestrant in ESR1-mutated advanced breast cancer (PDUFA December 18, 2026). Giredestrant establishes new adjuvant standard with significant iDFS benefit Tamoxifen and aromatase inhibitors face first adjuvant displacement in decades
Pipeline Watch
The NCI Clinical Trials Innovation Unit launched the PROSPECT-Lung trial (NCT06632327), the first trial from this new NCI unit, randomizing patients with resectable early-stage NSCLC to perioperative immunotherapy (neoadjuvant + adjuvant) versus adjuvant immunotherapy alone. The trial aims to determine whether adding pre-surgical checkpoint inhibitor treatment improves outcomes beyond post-surgical therapy alone, directly addressing the key sequencing question in early NSCLC. [Note: The original digest cited NCT07554846, which does not exist on ClinicalTrials.gov; this has been replaced with the verified PROSPECT-Lung trial addressing the same clinical question.]
The FDA granted Priority Review via Real-Time Oncology Review (RTOR) to BeOne Medicines' (Jazz Pharmaceuticals) sBLA for Ziihera (zanidatamab-hrii) in combination with chemotherapy ± tislelizumab (Tevimbra) for first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, according to CancerNetwork. The PDUFA target date is August 25, 2026. The Phase 3 HERIZON-GEA-01 trial (914 patients) showed median PFS of 12.4 vs 8.1 months (HR 0.63) and median OS of 26.4 vs 19.2 months (HR 0.72) for the zanidatamab triplet versus trastuzumab plus chemotherapy. Zanidatamab has Breakthrough Therapy Designation for this combination.
Competitive Landscape
The FDA approval of PROTAC-based Veppanu (vepdegestrant) alongside camizestrant's ODAC 6-3 vote creates distinct competitive tiers in ESR1-mutated breast cancer, per Fierce Pharma. PROTAC mechanism validated with first-ever approval Camizestrant's ctDNA-guided switch strategy faces regulatory uncertainty
| Company | Drug | Mechanism | Status |
|---|---|---|---|
| Arvinas/Pfizer | Vepdegestrant (Veppanu) | PROTAC degrader | FDA Approved (May 1) |
| AstraZeneca | Camizestrant | Oral SERD | ODAC 6-3 Against |
| Roche | Giredestrant | Oral SERD | lidERA positive; NDA under review |
AstraZeneca's 6-3 ODAC vote against camizestrant's ctDNA-guided switch strategy (SERENA-6: PFS 16.0 vs 9.2 months, HR 0.44) signals regulatory skepticism toward novel trial designs without mature OS data, according to Fierce Biotech. The vote reinforces CDK4/6 inhibitor + AI combination dominance in first-line treatment decisions.
Roche's giredestrant Phase III lidERA success (iDFS HR 0.70, p=0.0014, 4,170 patients) marks the first oral SERD to beat standard endocrine therapy in the adjuvant setting, per CancerNetwork. The 30% risk reduction in invasive disease recurrence opens the largest commercial opportunity in breast cancer endocrine therapy.
Forward Looking
- FDA final decision on camizestrant expected by mid-2026; the agency is not bound by the ODAC 6-3 vote, and AstraZeneca has indicated it will continue working with the FDA
- Arvinas and Pfizer on track to announce selection of third-party commercialization partner for Veppanu (vepdegestrant), potentially attracting major oncology players seeking PROTAC platform access
- Roche's giredestrant NDA for ESR1-mutated advanced breast cancer has a PDUFA target date of December 18, 2026; adjuvant filing based on lidERA data expected to follow
- Zanidatamab (Ziihera) sBLA PDUFA target date August 25, 2026 for first-line HER2+ GEA combinations with chemotherapy ± tislelizumab